



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Lifibrol

Cat. No.:	HY-124560
CAS No.:	96609-16-4
Molecular Formula:	C ₂₁ H ₂₆ O ₄
Molecular Weight:	342.43
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia ^{[1][2]} .								
In Vivo	<p>Lifibrol (15, 50 mg/kg; p.o.; daily for 6 days) decreases the plasma total cholesterol^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male TUC-Sprague-Dawley rats^[2]</td> </tr> <tr> <td>Dosage:</td> <td>15, 50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o; daily for 6 days</td> </tr> <tr> <td>Result:</td> <td>Decreased the plasma total cholesterol.</td> </tr> </table>	Animal Model:	Male TUC-Sprague-Dawley rats ^[2]	Dosage:	15, 50 mg/kg	Administration:	P.o; daily for 6 days	Result:	Decreased the plasma total cholesterol.
Animal Model:	Male TUC-Sprague-Dawley rats ^[2]								
Dosage:	15, 50 mg/kg								
Administration:	P.o; daily for 6 days								
Result:	Decreased the plasma total cholesterol.								

REFERENCES

- [1]. Locker PK, et al. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group. Clin Pharmacol Ther. 1995 Jan;57(1):73-88.
- [2]. Bell FP, et al. Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesi, and the fate of injected [¹⁴C]acetate. Lipids. 1993 Dec;28(12):1079-85.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA